Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03100136 · ClinicalTrials.gov registry record · Phase 1
Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03100136 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 7 participants.
The verdict
NCT03100136, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a study measuring the binding kinetics and test-retest characteristics of a subpharmacological dose of \[11C\]PF-06809247 Monoacylglycerol lipase (MAGL) Positron Emission Tomography (PET) tracer in healthy adult subjects.
Interventions
- DRUG [11C]PF-06809247
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-11-16 |
| Est. Completion | 2017-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03100136
The ClinicalTrials.gov registry entry for NCT03100136 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]PF-06809247 is the first listed.
NCT03100136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03100136 about?
NCT03100136 is a clinical study titled "Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer". This is a study measuring the binding kinetics and test-retest characteristics of a subpharmacological dose of \[11C\]PF-06809247 Monoacylglycerol lipase (MAGL) Positron Emission Tomography (PET) tracer in healthy adult subjects.
What is the current status of trial NCT03100136?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-11-16. Estimated completion is 2017-03-10.
What interventions are being tested in trial NCT03100136?
The interventions under investigation include: [11C]PF-06809247 (DRUG).
Who is sponsoring clinical trial NCT03100136?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.